Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DR-3001a · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DR-3001a | DRUG | 4mg daily vaginally |
| DR-3001b | DRUG | 6 mg vaginally daily |
| Placebo | OTHER | Administered vaginally to match experimental arms |
Inclusion Criteria: * Diagnosis of overactive bladder and incontinence for at least 6 months * Using birth control or menopausal * Willing to discontinue current medication for overactive bladder Exclusion Criteria: * Pregnant or given birth in the last 6 months * Three or more urinary tract infe...
DR-3001a is an investigational small molecule being developed for the treatment of urinary incontinence, specifically studied in women with overactive bladder. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
The molecular target of DR-3001a has not been disclosed. It is a small molecule being evaluated for its safety and efficacy in treating urinary incontinence, but the specific biological pathway it acts on has not been publicly identified.
DR-3001a is being developed by Teva Pharmaceutical Industries Limited, a company publicly traded under the ticker symbol TEVA. The drug is currently in Phase 2 clinical trials for urinary incontinence.
DR-3001a is in Phase 2 clinical development. It is an investigational drug and has not received regulatory approval. A Phase 2 trial evaluating its safety and efficacy in women with overactive bladder has been completed.
DR-3001a has one completed Phase 2 clinical trial, identified as NCT00196404. This randomized, double-blind, placebo-controlled study enrolled 800 women with overactive bladder across the United States and Canada to evaluate the drug's safety and efficacy.
DR-3001a is the drug name provided in the clinical trial data. No alternative names have been disclosed, so it is not known whether DR-3001a is the same as DR-3001 or any other compound.